76307432 - INVOLIN

Information

• Trademark
• 76307432

• Source

• Serial Number

  76307432

• Registration Number

  2954070

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  August 30, 2001
  24 years ago

• Registration Date

  May 24, 2005
  20 years ago

• Transaction Date

  February 07, 2012
  13 years ago

• Status Date

  December 30, 2011
  13 years ago

• Published for Opposition Date

  May 04, 2004
  21 years ago

• Location Date

  May 24, 2005
  20 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  CLARKE, IDI A

• Attorney Name

  Barry L. Kelmachter

  Law Office Assigned Location Code

  L10

• Owners

  • Cellectis S.A.

Case File Statements

• GS0011: chemical, biochemical, biotechnological products intended for industry, the sciences, agriculture, and horticulture, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research use; cells engineered by meganuclease recombination systems for scientific, laboratory or medical research; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research; deoxyribonucleic acid reagents for scientific research use, namely for the transport of biological molecules; microorganism cultures and preprations for use in the manufacture of human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; microorganisms used for producing therapeutic compounds or vaccines; microorganism cultures and preparations for medical research use, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for medical research use, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for use in the manufacture of human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of reagents and endocnuclease
• GS0051: Pharmaceutical, veterinary and health-care products, namely polypeptides for in vivo and in vitro genetic engineering for clinical use; natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease for clinical use; cells engineered by meganuclease recombination systems for clinical use; microorganism cultures and preparations for clinical medical use, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, and nucleic acid vectors; microorganism cultures and preparations for use as human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and microorganisms used for producing therapeutic compounds or vaccines; bacteriological preparations for clinical medical use, namely bacteriologic preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases and nucleic acid vectors; bacteriological preparations for use as human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; drugs for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; biological preparations for clinical medical use, namely polypeptides for in vivo in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemical biochemical preparations for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease, and cells engineered by meganuclease recombination systems; chemical and biochemical preparations for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemopharmaceutical products
• GS0421: Scientific and industrial research; research in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research in chemistry, biology, biochemistry, molecular biology, and bacteriology; research and development for others of techniques of biochemical analysis, biological analysis, and molecular biology techniques; scientific transgenesis research of deoxyribonucleic acid for the preparation or conveying of biological molecules; scientific analysis namely in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research and development for others of new molecules intended for industry; laboratory research in the fields of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; medical services; studies of technical projects in the field of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; testing, analysis and evaluation of engineering works for others; licensing of patents and intellectual property; computer programming for others, development for others of multimedia software programs

Case File Event Statements

• 12/30/2011 - 13 years ago

  26 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 5/24/2005 - 20 years ago

  25 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 3/25/2005 - 20 years ago

  24 - OPPOSITION TERMINATED NO. 999999 Type: OP.T

• 3/25/2005 - 20 years ago

  23 - OPPOSITION DISMISSED NO. 999999 Type: OP.D

• 9/9/2004 - 21 years ago

  22 - OPPOSITION INSTITUTED NO. 999999 Type: OP.I

• 6/2/2004 - 21 years ago

  21 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF

• 5/4/2004 - 21 years ago

  20 - PUBLISHED FOR OPPOSITION Type: PUBO

• 4/14/2004 - 21 years ago

  19 - NOTICE OF PUBLICATION Type: NPUB

• 2/10/2004 - 21 years ago

  18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 10/8/2003 - 22 years ago

  17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 10/18/2003 - 22 years ago

  16 - CASE FILE IN TICRS Type: CFIT

• 10/8/2003 - 22 years ago

  15 - FAX RECEIVED Type: FAXX

• 10/3/2003 - 22 years ago

  14 - CONTINUATION OF FINAL REFUSAL MAILED Type: CNCF

• 9/16/2003 - 22 years ago

  13 - PREVIOUS ACTION COUNT WITHDRAWN Type: ZZZY

• 9/15/2003 - 22 years ago

  12 - PREVIOUS ALLOWANCE COUNT WITHDRAWN Type: ZZZX

• 5/20/2003 - 22 years ago

  11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 5/12/2003 - 22 years ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 5/7/2003 - 22 years ago

  9 - CONTINUATION OF FINAL REFUSAL MAILED Type: CNCF

• 3/10/2003 - 22 years ago

  8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 3/10/2003 - 22 years ago

  7 - PAPER RECEIVED Type: MAIL

• 11/15/2002 - 23 years ago

  6 - FINAL REFUSAL MAILED Type: CNFR

• 11/14/2002 - 23 years ago

  5 - Sec. 1(B) CLAIM DELETED Type: 1.BD

• 10/8/2002 - 23 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 5/6/2002 - 23 years ago

  3 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/9/2001 - 24 years ago

  2 - NON-FINAL ACTION MAILED Type: CNRT

• 11/2/2001 - 24 years ago

  1 - ASSIGNED TO EXAMINER Type: DOCK